Suppr超能文献

S100/乳腺珠蛋白/SOX10/DOG1免疫组化表达模式在分泌性癌和腺泡细胞癌鉴别诊断中的应用价值:一项系统评价和Meta分析

Diagnostic Utility of Expression Pattern of S100/Mammaglobin/SOX10/DOG 1 Immunohistochemistry in Differentiation of Secretory and Acinic Cell Carcinoma: A Systematic Review and Meta-Analysis.

作者信息

Sharma Gitika, Kamboj Mala, Narwal Anjali, Keerthika R, Devi Anju, Vijayakumar Gopikrishnan

机构信息

Pandit Bhagwat Dayal Sharma, University of Health Sciences, Oral Pathology and Microbiology, Rohtak, Haryana 124001 India.

出版信息

Indian J Otolaryngol Head Neck Surg. 2024 Feb;76(1):208-218. doi: 10.1007/s12070-023-04127-z. Epub 2023 Aug 14.

Abstract

Secretory carcinoma (SC) is a relatively new disease entity, separate from acinic cell carcinoma (AciCC), which frequently displays ETV6-NTRK3 gene fusion. However, the differences between SC and AciCC remain ambiguous. Genetic diversity makes its diagnosis complicated. In this regard combined expression of immunohistochemistry markers S100/Mammaglobin/SOX10 and DOG1 is need of the hour as alternative methodology. The current systematic review was to investigate the diagnostic utility of combined immunohistochemical expression of S100/Mammaglobin/SOX10/DOG1 in distinction of SC from AciCC histologically. An electronic search of databases was carried out using MEDLINE by PubMed, Google scholar, Scopus and Web of science. Articles inclusive of SC and AciCC were assessed with S100/Mammaglobin/SOX10/DOG1 immunohistochemistry and their predominant expression pattern, predictive values, sensitivity and specificity were gathered. Fourteen eligible articles were analysed, which revealed predominant immunostaining pattern of S100 + /Mammaglobin + /SOX10 + /DOG1- by nearly all ETV6::NTRK3 fusion prevalent SCs alongside with other gene fusions like RET, MET and MAML3 with 98.4% sensitivity as well as 86.1% specificity. The evidence supports that S100/Mammaglobin/SOX10/DOG1 combined immunostaining can serve as a reliable diagnostic method to differentiate secretory from acinic cell carcinoma.

摘要

分泌性癌(SC)是一种相对较新的疾病实体,与腺泡细胞癌(AciCC)不同,后者常表现出ETV6-NTRK3基因融合。然而,SC和AciCC之间的差异仍不明确。基因多样性使其诊断变得复杂。在这方面,免疫组织化学标志物S100/乳腺珠蛋白/SOX10和DOG1的联合表达作为替代方法是当务之急。本系统评价旨在研究S100/乳腺珠蛋白/SOX10/DOG1联合免疫组织化学表达在组织学上区分SC和AciCC的诊断效用。通过PubMed、谷歌学术、Scopus和科学网对MEDLINE数据库进行电子检索。纳入SC和AciCC的文章采用S100/乳腺珠蛋白/SOX10/DOG1免疫组织化学进行评估,并收集其主要表达模式、预测值、敏感性和特异性。分析了14篇符合条件的文章,结果显示几乎所有携带ETV6::NTRK3融合的常见SC以及其他基因融合如RET、MET和MAML3的主要免疫染色模式为S100+ /乳腺珠蛋白+ /SOX10+ /DOG1-,敏感性为98.4%,特异性为86.1%。证据支持S100/乳腺珠蛋白/SOX10/DOG1联合免疫染色可作为区分分泌性癌和腺泡细胞癌的可靠诊断方法。

相似文献

引用本文的文献

本文引用的文献

2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验